NV-SPHERICAM
Sphericam 2, the world’s first 360˚ VR camera capable of self-stitching and livestreaming 4K video in real-time will start shipping this summer. Full-scale production is scheduled to begin at a U.S. production facility this July following a successful Kickstarter campaign and new $5 million investment from China’s Kingnet Technologies.
“The Sphericam 2 is like no other camera on the market. With a global shutter capable of shooting at 60 frames per second and the ability to self-stitch and livestream 4K video, it sets a new bar for performance. It’s also incredibly compact, roughly the size of a baseball. We designed the camera with professionals in mind which is why we’re thrilled use our presence at NAB to announce it will be available this summer” says Jeffrey Martin, Sphericam founder and CEO. The National Association of Broadcasters trade show in Las Vegas marks the first time the public will be able to view a live demo of the Sphericam 2.
The camera was first announced on Kickstarter in 2015 where it received backing of $450,000, more than four times the initial target.
“Our Kickstarter backers and pre-order customers will be the first to receive the Sphericam 2 once it ships. We also have large media and technology companies eager to start using the camera. The recent investment from Kingnet helps us not only accelerate our production timetable but to broaden our product and service portfolio,” says Martin.
The Shanghai-based online and mobile gaming company Kingnet is investing $5 million as part of a new strategic focus on VR content.
“We invested in Sphericam because it’s clear that it’s more than just a VR hardware company,” Wang Yue, CEO of Kingnet Technologies. “Sphericam is building a bridge between people’s real-world experiences and the VR space. The Sphericam 2 allows people to capture and share 360˚ video in a format that’s perfect for today’s virtual reality headsets and this is only the beginning.
Sphericam will be important part of Kingnet’s “platform+content+VR” strategy far into the future.”
The Sphericam 2 is available for pre-order at a cost of $2500.
Visit us at NAB 2016, Las Vegas, USA
April 16th – 21st
Booth N8022
North Hall, VR Pavilion
About Sphericam
Founded by American photographer Jeffrey Martin along with Dutch hardware specialist Servaes Joordens and software specialist Poppo Wit in 2014, Sphericam is dedicated to building groundbreaking 360˚ cameras to create original content for virtual reality platforms and interactive online media. The company’s newest product, called Sphericam 2, is an immersive capture device capable of self-stitching and streaming live 4K video at 60 frames per second. The company has offices in Prague, Haarlem, Haaren and Ljubljana.
Images and example 360˚ video content: http://bit.do/sphericam
View source version on businesswire.com: http://www.businesswire.com/news/home/20160417005021/en/
Contact:
Media contact
US:
Gaja Zornada
gaja@sphericam.com
+38-64-1215-430
+1-401-3-430-430
or
George
Krieger
press@sphericam.com
+1-831-717-7214
or
Europe:
Marc
Rettig
marc.Rettig@nelsonbostockunlimited.com
T
+44-7814-794253
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom